SBI 产品代理

ILT7(HZN-7734/VIB7734)

SBI-9674

SBI-3150
Cdc7(AS-0141)

SBI Biotech mainly focuses on dendritic cell platform-based   innovative drug development.

As an R&D-type bio-venture company, we do not have abundant   human resource like in the case of general pharmaceutical companies and we   mainly focus on our activity in the early stages of drug development. Particularly,   our biggest hurdle is the clinical studies / clincal trials which we need   huge budgets to support our clinical trials on human to test drug safety and   efficacy.

We have been trying to utilize our human and financial resources   efficiently by early licensing of our pipelines in the preclinical stage,   instead of performing the clinical trials by our own. For the early stage   licensing, we have tried to provide excellent products by the world-leading   research team with the expertise in dendritic cell manipulation. We have   successfully proven the feasibility of the business model since we succeeded   in licensing of our early stage dendritic cells targeting antibody, anti-ILT7   antibody to MedImmune. We will continue our efforts in early licensing   activity by our highly competitive research team.

On the other hand, recently, major pharmaceutical companies are   rather motivated to license-in the pipelines at advanced stages, such as the   one with established POC (Proof of Concept). Especially the nucleotide drugs   are the major examples for the pipelines with difficulty in early licensing;   there are not many products already approved and enough accumulation of data   on efficacy and side effects due to the lack of experience in such novel   species of drugs. Thus, we are also establishing the strategy to perform the   early stage of clinical trial by our own until obtaining POC, in parallel to   the licensing activities at early clinical stages.